Infect Chemother.  2010 Dec;42(6):397-403. 10.3947/ic.2010.42.6.397.

The Bacterial Etiology of Community-Acquired Pneumonia in Korea: A Nationwide Prospective Multicenter Study

• Chong YP
• Jung KS
• Lee KH
• Kim MN
• Moon SM
• Park S
• Hur J
• Kim DM
• Jeon MH
• Woo JH

• KMID: 2170319
• DOI: http://doi.org/10.3947/ic.2010.42.6.397

Abstract

BACKGROUND
Successful therapy for community-acquired pneumonia (CAP) requires appropriate empirical antimicrobial therapy based on the local microbe and resistance patterns. However, the available data on the bacterial etiology and antimicrobial susceptibility of CAP in Korea is very limited.
MATERIALS AND METHODS
A nationwide prospective multicenter study of CAP in adult patients was carried out between March 2009 and February 2010. Most patients underwent detailed assessment for bacterial and viral pathogens (cultures, urinary antigen testing, serological methods and polymerase chain reaction).
RESULTS
A total of 619 patients were studied. More than half (50.4%) of the patients were > or =65 years, 59.3% were males and 48.1% had underlying illness. The etiology was identified in 246 (39.7%) of the patients. The most common etiologic agent was Streptococcus pneumoniae (52 episodes, 21.1%), and the majority (36/52) of which were diagnosed by a positive urinary antigen test alone. The other common bacterial agents included Mycoplasma pneumoniae (41, 16.7%), Klebsiella pneumoniae (26, 10.6%), Chlamydia pneumoniae (13, 5.3%), Pseudomonas aeruginosa (11, 4.3%) and Staphylococcus aureus (8, 3.1%). All S. pneumoniae isolates were susceptible to penicillin with MIC of 2 microg/mL or less, only 1/16 (6.2%) was resistant to levofloxacin and 10/16 (62.5%) were resistant to erythromycin. Of the 26 K. pneumoniae isolates, 25 (96.2%) were susceptible to cefotaxime and ciprofloxacin.
CONCLUSIONS
S. pneumoniae remains the most frequent pathogen in adults with CAP and this should be covered with empirical antimicrobial treatment. Atypical pathogens such as M. pneumoniae and C. pneumoniae were the second most common etiologic agents and they should be tested for. The rate of CAP caused by gram-negative bacilli such as K. pneumoniae and P. aeruginosa was high, which is similar to that of the previous Korean studies. Further study, with excluding healthcare-associated pneumonia, is needed to clarify the etiology of CAP in Korea.

Keyword

Bacterial pneumonia; Community; Etiology; Resistance

MeSH Terms

Adult
Cefotaxime
Chlamydophila pneumoniae
Erythromycin
Humans
Klebsiella pneumoniae
Korea
Male
Mycoplasma pneumoniae
Ofloxacin
Penicillins
Pneumonia
Pneumonia, Bacterial
Pneumonia, Mycoplasma
Prospective Studies
Pseudomonas aeruginosa
Staphylococcus aureus
Streptococcus pneumoniae
Cefotaxime
Erythromycin
Ofloxacin
Penicillins

Reference

1. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001. 163:1730–1754.

2. Korea National Statistical Office. Annual report on the cause of death statistics 2007: Nation Wide. 2007. Daejeon: Korea National Statistical Office.

3. Apisarnthanarak A, Mundy LM. Etiology of community-acquired pneumonia. Clin Chest Med. 2005. 26:47–55.

4. Sohn JW, Park SC, Choi YH, Woo HJ, Cho YK, Lee JS, Sim HS, Kim MJ. Atypical pathogens as etiologic agents in hospitalized patients with community-acquired pneumonia in Korea: a prospective multi-center study. J Korean Med Sci. 2006. 21:602–607.

5. Woo JH, Kang JM, Kim YS, Shin WS, Ryu JH, Choi JH, Kim YR, Cheong HJ, Uh ST, Park CS, Chung MH, Chung KS, Lee CJ, Ryu J. A prospective multicenter study of community-acquired pneumonia in adults with emphasis on bacterial etiology. Korean J Infect Dis. 2001. 33:1–7.

6. Chung MH, Shin WS, Kim YR, Kang MW, Kim MJ, Jung HJ, Park SC, Pai H, Choi HJ, Shin HS, Kim EC, Choe KW, Kim S, Peck KR, Song JH, Lee K, Kim JM, Chong Y, Han SW, Lee KM. Etiology of communityacquired pneumonia surveyed by 7 university hospitals. Korean J Infect Dis. 1997. 29:339–359.

7. Song JH, Oh WS, Kang CI, Chung DR, Peck KR, Ko KS, Yeom JS, Kim CK, Kim SW, Chang HH, Kim YS, Jung SI, Tong Z, Wang Q, Huang SG, Liu JW, Lalitha MK, Tan BH, Van PH, Carlos CC, So T. Asian Network for Surveillance of Resistant Pathogens Study Group. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents. 2008. 31:107–114.

8. Yu CW, Park CW, Hwang BY, Song JY, Park O, Sohn JW, Cheong HJ, Kim WJ, Kim MJ, Park SC. Clinical features and prognosis of community-acquired pneumonia in the elderly patients. Korean J Infect Dis. 2000. 32:212–218.

9. Song JH, Jung KS, Kang MW, Kim DJ, Pai H, Suh GY, Shim TS, Ahn JH, Ahn CM, Woo JH, Lee NY, Lee DG, Lee MS, Lee SM, Lee YS, Lee H, Chung DR. Treatment guidelines for community-acquired pneumonia in Korea: an evidence-based approach to appropriate antimicrobial therapy. Infect Chemother. 2009. 41:133–153.

10. Clinical and Laboratory Standards Institue. CLSI document M100-S18. Performance standards for antimicrobial susceptibility testing. Eighteenth informational supplement. 2008. Wayne, PA: CLSI.

11. Charles PG, Whitby M, Fuller AJ, Stirling R, Wright AA, Korman TM, Holmes PW, Christiansen KJ, Waterer GW, Pierce RJ, Mayall BC, Armstrong JG, Catton MG, Nimmo GR, Johnson B, Hooy M, Grayson ML. Australian CAP Study Collaboration. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis. 2008. 46:1513–1521.

12. Díaz A, Barria P, Niederman M, Restrepo MI, Dreyse J, Fuentes G, Couble B, Saldias F. Etiology of community-acquired pneumonia in hospitalized patients in chile: the increasing prevalence of respiratory viruses among classic pathogens. Chest. 2007. 131:779–787.

13. Lee SJ, Lee MG, Jeon MJ, Jung KS, Lee HK, Kishimoto T. Atypical pathogens in adult patients admitted with community-acquired pneumonia in Korea. Jpn J Infect Dis. 2002. 55:157–159.

14. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997. 336:243–250.

15. Rosón B, Fernández-Sabé N, Carratalà J, Verdaguer R, Dorca J, Manresa F, Gudiol F. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis. 2004. 38:222–226.

16. Smith MD, Derrington P, Evans R, Creek M, Morris R, Dance DA, Cartwright K. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol. 2003. 41:2810–2813.

17. Klugman KP, Madhi SA, Albrich WC. Novel approaches to the identification of Streptococcus pneumoniae as the cause of community-acquired pneumonia. Clin Infect Dis. 2008. 47:Suppl 3. S202–S206.

18. Boulware DR, Daley CL, Merrifield C, Hopewell PC, Janoff EN. Rapid diagnosis of pneumococcal pneumonia among HIV-infected adults with urine antigen detection. J Infect. 2007. 55:300–309.

19. Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010. 50:202–209.

20. American Thoracic Society. Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005. 171:388–416.

21. Kollef MH, Morrow LE, Baughman RP, Craven DE, McGowan JE Jr, Micek ST, Niederman MS, Ost D, Paterson DL, Segreti J. Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes--proceedings of the HCAP Summit. Clin Infect Dis. 2008. 46:Suppl 4. S296–S334.